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BSF-2/IL-6, GM-CSF and IL-lfl mRNAs were induced by recombinant IL-I in human astrocytoma cell line U373MG. 
The induction of BSF-2/IL-6 and IL-lfl mRNAs did not require de novo protein synthesis while that of GM-CSF mRNA 
required a newly synthesized protein. Dexamethasone inhibited the induction of these cytokine mRNAs by IL-I. This 
process eems to require continued protein synthesis. These results suggest hat the production of these cytokines are 
positively and negatively controlled by IL-1 and glucocorticoids, respectively, in astrocytes. 
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1. INTRODUCTION 
Interleukin-1 is a cytokine which has multiple 
biological activities involved in the regulation of 
the immune, inflammatory, endocrine and central 
nervous system [1-4]. Its biological activities in- 
clude induction of various cytokines. IL-1 has been 
shown to induce the production of granulocyte- 
macrophage colony-stimulating factor [5-13], 
granulocyte CSF (G-CSF) [9-12] and B-cell 
stimulatory factor-2/interleukin-6/interferon-fl2 
(IFN-~2)/26-kDa protein [14-17]. Recently it has 
also been reported that IL-1 can induce its own 
synthesis [18-20]. However it has not been clear 
whether IL-1 can induce all of these cytokines in a 
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given cell type or different cells respond ifferently 
to IL-1 action. The role of IL-1 in regulation of the 
expression of various cytokines at its molecular 
level remains to be elucidated. 
Glucocorticoids, the immunosuppressive and 
anti-inflammatory agents, have been shown to 
decrease mitogen induced production of IL-2 [21], 
IL-3 [22] or GM-CSF [22,23], and also production 
of IL-1 by lipopolysaccharide (LPS) [24-28] or 
phorbol ester [29]. 
During the course of our studies on the effect of 
IL-1 on CSF production, we found that CSF ac- 
tivities were induced by IL-I in human 
astrocytoma cell line U373MG. Therefore we ex- 
amined what kind of cytokine mRNAs were in- 
duced by IL-1 as well as the regulatory mechanism 
of their induction by IL-1. We also studied 
glucocorticoids regulation of the induction of 
cytokine mRNAs by IL-1. In this paper, we 
describe that IL-1 induced BSF-2, GM-CSF and 
IL-lfl mRNAs in U373MG cells and dex- 
amethasone decreased the induced level of these 
mRNAs. 
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2. MATERIALS  AND METHODS 
2.1. Cell culture 
Human astrocytoma cell line U373MG was obtained from the 
American Type Culture Collection (ATCC). U373MG ceils 
were grown at 37°C in 90 mm-diameter dish in Eagle's minimal 
essential medium supplemented with 10070 fetal calf serum. 
Upon reaching confluence, the culture medium was then re- 
placed with fresh medium. The cells were treated with recombi- 
nant human IL-I# (rlL-l~, final concentration of 10 ng/ml) 
[30] alone, or rlL-1~ with cycloheximide (final concentration f 
10/~g/ml) and/or dexamethasone (final concentration of 
10 -6 M) for 8 h. 
2.2. RNA isolation and analysis 
At the end of the incubation period, cells were lysed in 
guanidine isothiocyanate nd total cellular RNA was isolated by 
centrifugation through cesium chloride cushions [31]. RNA 
samples (10/zg) were denatured with glyoxal-DMSO, elec- 
tropboresed in 1.2°70 agarose gel and blotted onto nitrocellulose 
membrane [32] or serial dilutions of the RNA samples were 
spotted onto nitrocellulose membrane [33]. Prehybridization 
and hybridization were carried out as described [32] with nick- 
translated cDNA probe. 
2.3. DNA probes 
BSF-2/IL-6 was detected using BSF-2 cDNA fragment 
(1.1 kb) isolated from plasmid pBSF-2.38.1 [34]. GM-CSF was 
detected using a Pstl-NcoI fragment (0.5 kb) of GM-CSF 
cDNA derived from pGM-CSF 22-25 isolated from PHA and 
PMA stimulated human tonsillar cDNA library (unpublished). 
IL-1,8 was detected using a PstI-PvulI fragment (0.7 kb) of 
IL-I~' cDNA from pcD-G1F-16 [35]. ~'-Actin DNA probe was 
purchased from Wako Pure Chemical Industries Ltd. 
3. RESULTS AND DISCUSSION 
In initial experiments,  we observed that BSF-2, 
GM-CSF  and IL - l f l  mRNAs  were induced by 
r lL- lce or r l L - l f l  in U373MG cells. Af ter  the addi-  
t ion of  r lL - l f l ,  BSF-2 mRNA was detectable after 
1 h which reached its max imum level at 4 h and 
then remained constant for at least addit ional  
12 h. On the other hand,  GM-CSF  and IL - l f l  
mRNAs  were detectable only 8 h after r l L - ld  
t reatment.  Moreover  the level of  these mRNAs  was 
lower than that of  BSF-2 (fig. 1). We have observed 
that G-CSF  mRNA was also induced although its 
level was very low (not shown), and therefore we 
did not study G-CSF  mRNA induct ion further. 
Seelentag et al. [10] have reported that IL-1 in- 
duced the expression of  GM-CSF ,  G-CSF and M- 
CSF mRNAs in human endothel ial  cells and 
Yasukawa et al. [17] have shown BSF-2 mRNA in- 
duct ion by r l L - l f l  in U373MG cells. Our results 
showed that IL- I~' induced not only GM-CSF  and 
Fig.1. Time course of BSF-2, GM-CSF and IL-1B mRNAs 
induction by rlL-lfl. U373MG cells were incubated for the 
indicated time periods with rlL-lfl. Total cellular RNA (10/zg) 
was subjected to Northern blot analysis. The blot was 
hybridized with the indicated 32p-labeled cDNA probe on the 
left of each panel. 
G -CSF  mRNAs but also those of  BSF-2 and IL - ld  
in ast rocytoma cell line. This suggests that IL-1 can 
induce the product ion of  several cytokines in the 
same cell. 
The requirement for newly synthesized proteins 
in the induct ion o f  these cytokine mRNAs  was ex- 
p lored by the use of  cycloheximide, an inhibitor of  
protein synthesis. The level of  BSF-2 and IL - ld  
mRNAs  induced by r l L - l~  increased in the 
presence of  cycloheximide. On the other hand, the 
level of  GM-CSF  mRNA induced by r l L - lg  
decreased markedly  in the presence of  cyclohex- 
imide. The level of  ~'-actin mRNA remained un- 
changed (figs 2 and 4). These data indicate that the 
induct ion of  BSF-2 and IL - l f l  mRNAs  by rlL-l~? 
does not require de novo protein synthesis, while 
GM-CSF  mRNA induct ion by r l L - l f l  is dependent 
upon de novo protein synthesis. Therefore it ap- 
pears that BSF-2 and IL - l f l  mRNAs  induct ion by 
r l L - l f l  might be regulated by a common 
mechanism. It is not clear whether GM-CSF  
mRNA induct ion by IL-1 is a consequence of  
direct act ion of  IL-1 or is brought about by a pro- 
tein ( intracel lular or secreted) that is synthetical ly 
regulated by IL-1. Therefore it is possible that 
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Fig.2. Effect of  cycloheximide on the induction of  BSF-2, GM-CSF and IL-I~ mRNAs by rlL-l~'. U373MG cells were incubated for 
8 h in the presence (+)  of  rIL-l~' with (+)  or without ( - )  cycloheximide (CHX). RNA was analyzed as described in the legend to 
fig.1, cDNA probes used are shown at the bottom of each panel. Molecular size markers of RNA (BRL) are shown on the right of  
each panel. 
mRNAs for various cytokines may be regulated en- 
tirely by different mechanisms by IL-1 in the same 
cell line. 
~b 
Seelentag et al. [10] have described that the in- 
duction of GM-CSF mRNA by IL-1 in human en- 
dothelial cells was not affected by dexamethasone, 
while Thorens et al. [23] have reported that dex- 
amethasone completely prevented GM-CSF 
mRNA induction by LPS. We therefore studied 
the effect of dexamethasone on the induction of 
BSF-2, GM-CSF and IL-I~' mRNAs by rIL-l~'. 
Our results showed that dexamethasone blocked 
the induction of these cytokine mRNAs by r IL- ld 
(fig.4). As shown in fig.3, dexamethasone in- 
hibited rIL- l~ induced GM-CSF mRNA level in a 
Fig.3. Concentration dependence of  dexamethasone inhibition 
on GM-CSF mRNA induction. U373MG cells were incubated 
for 8 h in the presence (+)  of rIL-l~' with the indicated 
concentration of  dexamethasone (DEX). RNA was analyzed as 
described in the legend to fig.1. Molecular size markers are 
described in the legend to fig.2. 
Fig.4. Effect of  dexamethasone and cycloheximide on the 
induction of BSF-2, GM-CSF and IL-I~' mRNAs by rlL-l~. 
U373MG cells were incubated for 8 h with ( + ) or without ( - ) 
the indicated reagents. The indicated amount of total cellular 
RNA was applied onto nitrocellulose filter. The filter was 
hybridized with the cDNA probe indicated at the bottom of 
each panel. 
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dose-dependent fashion. The suppressive dose 
range (10-6-10 -8 M) of  dexamethasone was in the 
pharmacologica l  to physiological  range. We also 
observed a dexamethasone dose-dependent 
decrease in the level of  BSF-2 and IL - l f l  mRNAs  
induct ion by r IL - l f l  (not shown). Therefore 
glucocort icoids may inhibit not only mitogen or 
LPS induced product ion of  cytokines shown in 
several reports [21-29], but also the product ion of  
cytokines induced by I L - l .  
It has been shown that mRNA induct ion by dex- 
amethasone does not require de novo protein syn- 
thesis [36]. However it is not clear whether 
dexamethasone inhibit ion of  mRNA induct ion re- 
quires de novo protein synthesis or not. Fig.4 
shows that accumulat ion of  BSF-2 and IL - I~  
mRNAs by r IL - l f l  is not inhibited by dex- 
amethasone in the presence of  cycloheximide. Our 
results indicate that dexamethasone inhibit ion of  
BSF-2 and IL - l f l  mRNAs  induct ion require de 
novo protein synthesis. The accumulat ion of  GM- 
CSF mRNA might be also inhibited by dex- 
amethasone in the similar mechanism. Therefore 
as yet undiscovered gene product(s) that may be in- 
duced by dexamethasone might be involved in the 
decrease of  the level of  BSF-2, GM-CSF  and IL - l f l  
mRNAs .  
It has been reported that astrocytes produce IL-1 
[37] and IL-1 stimulates the prol i ferat ion of  
astrocytes [38]. Our results suggest that IL-1 in- 
duces the product ion of  several cytokines and 
glucocort icoids regulate their product ion negative- 
ly in astrocytes. These cytokines that are differen- 
tial ly regulated by IL-1 and glucocort icoids may 
play important  roles in central nervous system. 
The regulatory mechanism of  the expression of  
these cytokines might be also common to the target 
cells of  IL-1. 
Acknowledgements: We .thank Dr Tadamitsu Kishimoto 
(Osaka University) for generously providing plasmid 
pBSF-2.38.1. We also thank Dr T. Venkat Gopal (Maryland 
Research Laboratories, Otsuka Pharmaceutical Co.) for critical 
reading of the manuscript. 
REFERENCES 
[1] Dinarello, C.A. (1987) in: Inflammation: Basic Principles 
and Clinical Correlates (Gallin, J.I. et al. eds) 
pp.195-208, Raven, New York. 
[2] Bernton, E.W., Beach, J.E., Holaday, J.W., Smallridge, 
R.C. and Fein, H.G. (1987) Science 238, 519-521. 
[3] Sapolsky, R., Rivier, C., Yamamoto, G., Plotsky, P. and 
Vale, W. (1987) Science 238, 522-524. 
[4] Berkenbosch, F., Van Oers, J., Del Rey, A., Tilders, F. 
and Besedovsky, H. (1987) Science 238, 524-526. 
[5] Lovhaug, D., Pelus, L.M., Nordlie, E.M., Boyum, A. 
and Moore, M.A.S. (1986) Exp. Hematol. 14, 1037-1042. 
[6] Bagby, G.C., jr, Dinarello, C.A., Wallace, P., Wagner, 
C., Hefeneider, S. and McCall, E. (1986) J. Clin. Invest. 
78, 1316-1323. 
[7] Fibbe, W.E., Van Damme, J., Billiau, A., Voogt, P.J., 
Duinkerken, N., Kluck, P.M.C. and Falkenburg, J.H.F. 
(1986) Blood 68, 1316-1321. 
[8] Sieff, C.A., Tsai, S. and Failer, D.V. (1987) J. Clin. 
Invest. 79, 48-51. 
[9] Rennick, D., Yang, G., Gemmell, L. and Lee, F. (1987) 
Blood 69, 682-691. 
[10] Seelentag, W.K., Mermod, J.-J., Montesano, R. and 
Vassalli, P. (1987) EMBO J. 6, 2261-2265. 
[11] Broudy, V.C., Kaushansky, K., Harlan, J.M. and 
Adamson, J.W. (1987) J. Immunol. 139, 464-468. 
[12] Kaushansky, K., Lin, N. and Adamson, J.W. (1988) J. 
Clin. Invest. 81, 92-97. 
[13] Herrmann, F., Oster, W., Meuer, S.C., Lindemann, A. 
and Mertelsmann, R.H. (1988) J. Clin. Invest. 81, 
1415-1418. 
[14] Kohase, M., May, L.T., Tamm, l., Vilcek, J. and Sehgal, 
P.B. (1987) Mol. Cell. Biol. 7, 273-280. 
[15] Defilippi, P., Poupart, P., Tavernier, J., Fiers, W. and 
Content, J. (1987) Proc. Natl. Acad. Sci. USA 84, 
4557-4561. 
[16] Walther, Z., May, L.T. and Sehgal, P.B. (1988) J. 
Immunol. 140, 974-977. 
[17] Yasukawa, K., Hirano, T., Watanahe, Y., Muratani, K., 
Matsuda, T., Nakai, S. and Kishimoto, T. (1987) EMBO 
J. 6, 2939-2945. 
[18] Warner, S.T.C., Auger, K.R. and Libby, P. (1987) J. 
Exp. Med. 165, 1316-1331. 
[19] Dinarello, C.A., Ikejima, T., Warner, S.J.C., Orencole, 
S.F., Lonnemann, G., Cannon, J.G. and Libby, P. (1987) 
J. Immunol. 139, 1902-1910. 
[20] Warner, S.J.C., Auger, K.R. and Libby, P. (1987) .1. 
lmmunol. 139, 1911-1917. 
[21] Arya, S.K., Wong-Staal, F. and Gallo, R.C. (1984) J. 
Immunol. 133, 273-276. 
[22] Culpepper, J.A. and Lee, F. (1985) J. Immunol. 135, 
3191-3197. 
[23] Thorens, B., Mermod, J.-J. and Vassalli, P. (1987) Cell 
48, 671-679. 
[24] Snyder, D.S. and Unanue, E.R. (1982) J. lmmunol. 129, 
1803-1805. 
[25] Knudsen, P.J., Dinarello, C.A. and Strom, T.B. (1987) J. 
lmmunol. 139, 4129-4134. 
[26] Kern, J.A., Lamb, R.J., Reed, J.C., Daniele, R.P. and 
Nowell, P.C. (1988) J. Clin. Invest. 81, 237-244. 
[27] Lee, S.W., Tsou, A.-P., Chan, H., Thomas, J., Petrie, 
K., Eugui, E.M. and Allison, A.C. (1988) Proc. Natl. 
Acad. Sci. USA 85, 1204-1208. 
[28] Lew, W., Oppenheim, J.J. and Matsushima, K. (1988) J. 
Immunol. 140, 1895-1902. 
28 
Volume 243, number 1 FEBS LETTERS January 1989 
[29] Nishida, T., Takano, M., Kawakami, T., Nishino, N., 
Nakai, S. and Hirai, Y. (1988) Biochem. Biophys. Res. 
Commun., in press. 
[30] Kikumoto, Y., Hong, Y.-M., Nishida, T., Nakai, S., 
Masui, Y. and Flirai, Y. (1987) Biochem. Biophys. Res. 
Commun. 147, 315-321. 
[31] Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J. and 
Rutter, W.J. (1979) Biochemistry 18, 5294-5299. 
[32] Thomas, P.S. (1980) Proc. Natl. Acad. Sci. USA 77, 
5201-5205. 
[33] Davis, L.G., Dibner, M.D. and Battey, J.F. (1986) in: 
Basic Methods in Molecular Biology, pp.147-149, 
Elsevier, New York. 
[34] Hirano, T., Yasukawa, K., Harada, H., Taga, T., 
Watanabe, Y., Matsuda, T., Kashiwamura, S., 
Nakajima, K., Koyama, K., Iwamatsu, A., Tsunasawa, 
S., Sakiyama, F., Matsui, H., Takahara, Y., Taniguchi, 
T. and Kishimoto, T. (1986) Nature 324, 73-76. 
[35] Nishida, T., Nishino, N., Takano, M., Kawai, K., Bando, 
K., Masui, Y., Nakai, S. and Hirai, Y. (1987) Biochem. 
Biophys. Res. Commun. 143, 345-352. 
[36] Karin, M., Andersen, R.D., Slater, E., Smith, K. and 
Herschman, H.R. (1980) Nature 286, 295-297. 
[37] Benveniste, E.N., Kutsunai, S. and Merrill, J.E. (1986) 
in: Leukocytes and Host Defence (Oppenheim, J.J. and 
Jacobs, D.M. eds) Progress in Leukocyte Biology, vol.5, 
pp.221-226. 
[38] Giulian, D. and Lachman, L.B. (1985) Science 228, 
497-499. 
29 
